Literature DB >> 1689345

Competition between foreign and self proteins in antigen presentation. Ovalbumin can inhibit activation of myelin basic protein-specific T cells.

A M Gautam1, P Glynn.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is an inflammatory neurological disease initiated by activated T cells specific for the autoantigen, myelin basic protein (MBP). The ability of Lewis rat splenic T cells to transfer EAE after in vitro incubation with MBP-pulsed dendritic cells (DC) was used as an index of MBP-specific T cell activation. OVA, previously processed by macrophages, was incubated with MBP and DC at the pulsing stage to determine whether it could inhibit presentation of the autoantigen. At molar equivalents of 2.5:1 and 20:1 relative to MBP, processed OVA increasingly inhibited the ability of DC to activate MBP-specific T cells for EAE transfer. Unprocessed OVA, which cannot be presented immunogenically by Lewis rat DC, was much less effective. However, processed OVA added to DC after they had been pulsed with MBP could not compete. OVA also blocked appearance of EAE when mixed with MBP/CFA in the inoculum used for active induction of the disease. Splenic T cells from MBP + OVA/CFA-immunized rats transferred EAE with a substantially delayed onset, suggesting that a reduced number of MBP-specific T cells was generated by immunizing with the OVA + MBP mixture compared with MBP alone. Overall, the data indicate that fragments of a foreign protein, OVA, which can be bound by APC, can also inhibit presentation of encephalitogenic determinants of MBP to T cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689345

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.

Authors:  D E Smilek; D C Wraith; S Hodgkinson; S Dwivedy; L Steinman; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

2.  Resource competition as a mechanism for B cell homeostasis.

Authors:  A R McLean; M M Rosado; F Agenes; R Vasconcellos; A A Freitas
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 3.  Overview of vaccines.

Authors:  G Ada
Journal:  Mol Biotechnol       Date:  1997-10       Impact factor: 2.695

4.  A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses.

Authors:  Y Katz-Levy; M Paas-Rozner; S Kirshner; M Dayan; E Zisman; M Fridkin; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

6.  Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor.

Authors:  M P Protti; A A Manfredi; X D Wu; L Moiola; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

7.  Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones.

Authors:  M Fridkis-Hareli; E F Rosloniec; L Fugger; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  Antigen-driven bystander suppression after oral administration of antigens.

Authors:  A Miller; O Lider; H L Weiner
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

9.  A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis.

Authors:  A M Gautam; C I Pearson; D E Smilek; L Steinman; H O McDevitt
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.